GLP‑1 drugs show cardiovascular benefits and potential aggression link, studies reveal

Research on the GLP‑1 agonist semaglutide, marketed as Ozempic, Wegovy and Mounjaro, indicates a 20 % reduction in heart attack, stroke and cardiovascular‑related death among overweight and obese adults. The randomized trial involved 17,604 participants from 41 countries and lasted an average of 40 months; serious cardiovascular events occurred in 6.5 % of the semaglutide group versus 8 % with placebo. Benefits were observed regardless of weight loss, and meta‑analyses published in The Lancet confirm lower risks of cardiovascular incidents and heart‑failure hospitalisation for GLP‑1 drugs, suggesting therapeutic value beyond glucose control.

Separate observations raise a possible connection between GLP‑1 therapy and behavioural changes such as impulsivity and aggression. Reports note increased irritability in some users, while other patients experience calmness or reduced energy. The findings are anecdotal and warrant further investigation to clarify any neuro‑psychiatric effects of these medications.